Please assess the completion status of the following clinical trial:

Trial Title: Adjunctive Curcumin for Symptomatic Adolescents With Bipolar Disorder: Brain and Body Considerations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* English speaking~* all races and ethnicities~* bipolar disorder I or II~* currently treated with lithium, divalproex, lamotrigine, and/or second generation antipsychotic~* doses stable for greater than or equal to 4 weeks~* current CGI BP score of moderate or greater~* current CDRS-R severity of greater than or equal to 35~Exclusion Criteria:~* If female, pregnant or sexually active without reliable contraception~* significant suicidal ideations (as determined by clinical interview or CDRS-R \> 3) and/or any suicidal intent, even if fleeting or non-recurrent, in the preceding 2 weeks~* substance dependence within the past 2 months~* daily antidepressant, glucocorticoid, nonsteroidal anti-inflammatory, anti-platelet, anti-coagulant, antacid, or oral hypoglycemic medication or insulin; high-dose antioxidant vitamin supplements or other natural health products that may function as an antidepressant within 30 days of baseline~* IQ\<80 or autistic disorder~* full threshold mania and/or YMRS \> 20 and/or psychosis~* hypersensitivity to curcumin/turmeric, gelatin~* dietary consumption of curcumin/turmeric \> 3 times/week~* clinically significant or unstable medical disorder; known gallstones and/or bile duct obstruction, stomach ulcers, excessive stomach acid/heartburn/gastroesophageal reflux disease (GERD); or clinically significant baseline laboratory abnormalities; or ALT and /or AST above the upper limit of normal on repeat examination at baseline~* severe depression (CDRS-R \> 98) and/or severely ill (CGI BP \>5)

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- adjunctive curcumin (Type: EXPERIMENTAL): Curcumin will be added to their current medications for 8 weeks. Starting dose will be 500mg daily, increased to 500mg twice daily in week 2, then increased to 1000mg twice daily during weeks 3-8. A slower titration will be used for subjects who demonstrate tolerability problems.

Based on this trial design, predict the completion outcome and termination type (if applicable).